ncRNA basic information
ncRNA ID:
MI0000272
ncRNA Database:
miRBase
ncRNA Name:
miR-182
ncRNA Type:
miRNA
ncRNA Expression:
down-regulated
ncRNA Method:
RT-PCR
ncRNA Target Gene:
MET
ncRNA Pathway:
MET/PI3K/AKT/mTOR signaling pathway
Evidence (ncRNA-drug):
validated
drug basic information
Drug ID:
DB00072 (BTD00098, BIOD00098)
Drug Name:
Trastuzumab
Drug Method:
The purpose of the current study was to investigate the function of miR-182 in trastuzumab resistance in breast cancer cells. The results showed that both breast cancer SKBR3 trastuzumab-resistant cells (SKBR3/TR) and BT474 trastuzumab-resistant cells (BT474/TR) were associated with miR-182 downregulation compared with their parental cells. Ectopic expression of the miR-182 mimic inhibited trastuzumab resistance, decreasing the invasion and migration of these trastuzumab-resistant cells. However, the miR-182 inhibitor increased trastuzumab resistance, cell invasion, and migration in the parental cells. In addition, MET is a directly targeted gene of miR-182 in breast cancer cells. MET knockdown showed an inhibitory effect of trastuzumab resistance on trastuzumab-resistant cells. In contrast, MET overexpression in SKBR3 cells produced an effect that promotes resistance to trastuzumab. Moreover, we revealed that overexpression of miR-182 reduced trastuzumab resistance in trastuzumab-resistant cells due in part to MET/PI3K/AKT/mTOR signaling pathway inactivation. Furthermore, miR-182 could also sensitize SKBR3/TR cells to trastuzumab in vivo.
Drug Response:
resistant
Cancer basic information
Cancer:
breast cancer
Tissue/Cell:
cell line (SKBR3,BT474)
Other information
Title:
miR-182 regulates trastuzumab resistance by targeting MET in breast cancer cells.
Journal:
Cancer Gene Ther
Published:
2019
PubMed ID:
29925897